p53-stabilizing agent CP-31398 prevents growth and invasion of urothelial cancer of the bladder in transgenic UPII-SV40T mice

Neoplasia (United States)

Volumn 15, Issue 8, 2013, Pages 966-974

  Madka, Venkateshwar ^a   Zhang, Yuting ^a   Li, Qian ^a   Mohammed, Altaf ^a   Sindhwani, Puneet ^a   Lightfoot, Stan ^a   Wu, Xue Re ^b   Kopelovich, Levy ^c   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL) QUINAZOLINE; 4 (3 DIMETHYLAMINOPROPYLAMINO) 2 (4 METHOXYSTYRYL)QUINAZOLINE; LIPOCORTIN 5; PROTEIN BAX; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BODY WEIGHT; CANCER GROWTH; CANCER INCIDENCE; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; GENOTYPE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION;

EID: 84881077064     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13704     Document Type: Article

References (49)

1. American Cancer Society (ACS) (2013). Cancer Facts & Figures 2013. American Cancer Society, Atlanta, GA.
2. Schalken JA, van Moorselaar RJ, Bringuier PP, and Debruyne FM (1992). Critical review of the models to study the biologic progression of bladder cancer. Semin Surg Oncol 8, 274-278.
3. Steinberg GD, Trump DL, and Cummings KB (1992). Metastatic bladder cancer. Natural history, clinical course, and consideration for treatment. Urol Clin North Am 19, 735-746.
4. Dalbagni G, Presti J, Reuter V, Fair WR, and Cordon-Cardo C (1993). Genetic alterations in bladder cancer. Lancet 342, 469-471.
5. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner S. P, Schmutte C, Yang AS, Cote R, et al. (1994). Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54, 784-788.
6. Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ, and Waldman F. M (1995). Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 26, 970-978.
7. Foster BA, Coffey HA, Morin MJ, and Rastinejad F (1999). Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510.
8. Wang W and El-Deiry WS (2008). Restoration of p53 to limit tumor growth. Curr Opin Oncol 20, 90-96.
9. Wiman KG (2007). Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Adv Cancer Res 97, 321-338.
10. Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, and Athar M (2007). CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 117, 3753-3764.
11. Rao CV, Swamy MV, Patlolla JM, and Kopelovich L (2008). Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res 68, 7670-7675.
12. Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, and Kopelovich L (2009). Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res 69, 8175-8182.
13. Zhang Z, Pak J, Shapiro E, Sun T, and Wu X (1999). Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 59(14), 3512-3517.
14. Ahuja D, Sáenz-Robles MT, and Pipas JM (2005). SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene 24(52), 7729-7745.
15. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25(4), 402-408.
16. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, and Boyle P (2008). Tobacco smoking and cancer: a meta-analysis. Int J Cancer 122, 155-164.
17. Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz P. I, Novara G, Robinson BD, et al. (2012). Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 63(4), 724-732.
18. Prout GR (1997). Bladder carcinoma and a TNM system of classification. J Urol 117, 583-588.
19. Grippo PJ and Sandgren EP (2000). Highly invasive transitional cell carcinoma of the bladder in a simian virus 40 T-antigen transgenic mouse model. Am J Pathol 157, 805-813.
20. Choi J-W, Kim Y, Lee J-H, and Kim Y-S (2013). CD74 expression is increased in high-grade, invasive urothelial carcinoma of the bladder. Int J Urol 20, 251-255.
21. Cohen SM (1998). Urinary bladder carcinogenesis. Toxicol Pathol 26, 121-127.
22. Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill D. L, and Seibert K (2000). Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60(20), 5599-5602.
23. Vinh PQ, Sugie S, Tanaka T, Hara A, Yamada Y, Katayama M, Deguchi T, and Mori H (2002). Chemopreventive effects of a flavonoid antioxidant silymarin on N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Jpn J Cancer Res 93(1), 42-49.
24. Sato D and Matsushima M (2003). Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int J Urol 10(3), 160-166.
25. Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, and Agarwal R (2007). Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 6(12 pt 1), 3248-3255.
26. Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, and Grubbs CJ (2008). Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl-(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer 123(10), 2254-2259.
27. Fragoso MF, Prado MG, Barbosa L, Rocha NS, and Barbisan LF (2012). Inhibition of mouse urinary bladder carcinogenesis by açai fruit (Euterpe oleraceae Martius) intake. Plant Foods Hum Nutr 67(3), 235-241.
28. Green JE, Shibata MA, Shibata E, Moon RC, Anver MR, Kelloff G, and Lubet R (2001). 2-Difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res 61, 7449-7455.
29. Perez-Stable CM, Schwartz GG, Farinas A, Finegold M, Binderup L, Howard G. A, and Roos BA (2002). The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer: target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Cancer Epidemiol Biomarkers Prev 11, 555-563.
30. Baratin M, Ziol M, Romieu R, Kayibanda M, Gouilleux F, Briand P, Leroy P, Haddada H., Rénia L, Viguier M, et al. (2001). Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-γ delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther 8, 193-202.
31. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, and Hanahan D (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93, 2002-2007.
32. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P., Itohara S, Werb Z, et al. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2, 737-744.
33. Degraff DJ, Robinson VL, Shah JB, Brandt WD, Sonpavde G, Kang Y, Liebert M., Wu XR, and Taylor JA (2013). Current preclinical models for the advancement of translational bladder cancer research. Mol Cancer Ther 12(2), 121-130.
34. Liu Z, Li X, Liu S, Xu X, Tian X, Simoneau AR, Wu RU, and Zi X (2012). Flavokawain A inhibits urinary bladder carcinogenesis in the UPII-SV40T transgenic mouse bladder cancer model. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; Abstract: 619.
35. Johnson AM, O'Connell MJ, Messing EM, and Reeder JE (2008). Decreased bladder cancer growth in parous mice. Urology 72(3), 470-473.
36. Li Y, Izumi K, and Miyamoto H (2012). The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol 42(7), 569-577.
37. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, and el-Deiry WS (2002). The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1(1), 47-55.
38. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, and Weller M (2003). CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22(51), 8233-8245.
39. Xu J, Timares L, Heilpern C, Weng Z, Li C, Xu H, Pressey JG, Elmets CA, Kopelovich L., and Athar M (2010). Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res 70(16), 6566-6576.
40. Roh JL, Kang SK, Minn I, Califano JA, Sidransky D, and Koch WM (2011). p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncol 47(1), 8-15.
41. Fiorini C, Menegazzi M, Padroni C, Dando I, Dalla Pozza E, Gregorelli A, Costanzo C., Palmieri M, and Donadelli M (2012). Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. Apoptosis 18(3), 337-346.
42. Muret J, Hasmim M, Stasik I, Jalil A, Mallavialle A, Nanbakhsh A, Lacroix L, Billot K., Baud V, Thiery J, et al. (2012). Attenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 function. PLoS One 7(6), e38808.
43. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, Groshen S., Taylor CR, Jones PA, Skinner DG, et al. (1998). Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90(14), 1072-1079.
44. Hong SH, Choi YS, Cho HJ, Lee JY, Hwang TK, and Kim SW (2012). Induction of apoptosis of bladder cancer cells by zinc-citrate compound. Korean J Urol 53(11), 800-806.
45. Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, and Harris A. L (1997). Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57, 5281-5285.
46. Yang CC, Chu KC, and Yeh WM (2004). The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 22, 1-6.
47. Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G, and Bittard H (2001). Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 166, 1275-1279.
48. Inoue K, Slaton JW, Davis DW, Hicklin DJ, McConkey DJ, Karashima T, Radinsky R., and Dinney CP (2000). Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 6, 2635-2643.
49. Zhang L, Yu D, Hu M, Xiong S, Lang A, Ellis LM, and Pollock RE (2000). Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 60, 3655-3661.